Janice Schakowsky actually said...

"drug manufacturers are gaming the system to make more money at consumers' expense, and that has to stop."

"Product hopping or evergreening is the reformulation of a drug by a brand-name manufacturer to delay competition and protect protection for profit."

"If PBMs were doing such a good job on my behalf negotiating for Part D, for example, why am I paying so much more than those other countries?"

"The time I believe to act is now."